RU97121002A - USE OF R-ENANTIOMER OF N-PROPARGYL-1-AMINOINDANE, ITS SALTS AND COMPOSITIONS CONTAINING THEM - Google Patents

Claims (9)

1. The use of R (+) - N-propargyl-1-aminoindan or its pharmaceutically acceptable salt for the preparation of a pharmaceutical composition for the treatment of cerebral ischemia, stroke, damage to a head injury, damage to a spinal injury, neurotrauma, neurodegenerative disease or neurotoxic lesion; or to prevent nerve damage in a subject.  2. The use according to claim 1, where in the treatment of cerebral ischemia or stroke, the area of ischemic brain damage is reduced by 35%.  3. The use according to claim 1, where the nervous disorder is a violation of the structure of the nerve or a violation of the structure of the optic nerve.  4. The use according to any one of claims 1 to 3, wherein the pharmaceutically acceptable salt of R (+) - N-propargyl-1-aminoindan is selected from the group consisting of: a mesylate salt; ethyl sulfonate salt; sulfate salt and hydrochloride salt.  5. The use according to any one of claims 1 to 4, where the effective amount of R (+) - N-propargyl-1-aminoindane or its pharmaceutically acceptable salt to be administered is 0.5 to 2.5 mg / kg body of the subject.  6. The use according to any one of claims 1 to 5, wherein R (+) - N-propargyl-1-aminoindane or a pharmaceutically acceptable salt thereof is administered intravenously, orally, rectally, transdermally or parenterally.  7. The use according to any one of claims 1 to 4, where the subject is a person and an effective amount is 0.01 to 50.0 mg per day.  8. The use of claim 7, wherein the effective amount is 0.1 to 10.0 mg per day.  9. The use of claim 7 or 8, wherein R (+) - N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is administered intravenously.